Literature DB >> 30848215

Corilagin Inhibits Esophageal Squamous Cell Carcinoma by Inducing DNA Damage and Down-Regulation of RNF8.

Fanghua Qiu1, Lifang Liu2, Yu Lin3, Zetian Yang2, Feng Qiu4.   

Abstract

BACKGROUND: Esophageal squamous cell carcinoma (ESCC), the most prevalent histologic subtype of esophageal cancer, is an aggressive malignancy with poor prognosis and a high incidence in the East. Corilagin, an active component present in Phyllanthus niruri L., has been shown to suppress tumor growth in various cancers. However, the effects of corilagin on ESCC and the mechanisms for its tumor suppressive function remain unknown.
METHODS: Cell proliferation was measured by Cell Counting Kit-8 assay and colony formation assays. Annexin V/PI double-staining was performed to assess cell apoptosis. Immunofluorescence staining and western blotting were used to evaluate the protein expression. A xenograft mice model was used to assess the in vivo antitumor effects of corilagin alone or in combination with cisplatin.
RESULTS: We for the first time showed that corilagin was effectively able to inhibit ESCC cell proliferation and induce cell apoptosis. Additionally, our results validated its antitumor effects in vivo using a xenograft mouse model. Mechanistically, we found that corilagin caused significant DNA damage in ESCC cells. We found that corilagin could significantly attenuate the expression of the E3 ubiquitin ligase RING finger protein 8 (RNF8) through ubiquitin-proteasome pathway, leading to the inability of DNA damage repair response and eventually causing cell apoptosis. Furthermore, we also showed that corilagin substantially enhanced the antitumor effects of chemotherapy drug cisplatin both in vitro and in vivo.
CONCLUSION: Our results not only provided novel and previously unrecognized evidences for corilagin-induced tumor suppression through inducing DNA damage and targeting RNF8 in ESCC, but also highlighted that corilagin might serve as an adjunctive treatment to conventional chemotherapeutic drugs in ESCC patients. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Corilagin; DNA damage; RNF8; chemosensitivity; cisplatin; esophageal squamous cell carcinoma.

Mesh:

Substances:

Year:  2019        PMID: 30848215     DOI: 10.2174/1871520619666190307120811

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  4 in total

1.  Corilagin induces apoptosis and autophagy in NRF2‑addicted U251 glioma cell line.

Authors:  Jilan Liu; Xianyun Qin; Wenyuan Ma; Shu Jia; Xiaobei Zhang; Xinlin Yang; Dongfeng Pan; Feng Jin
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

2.  Corilagin induces human glioblastoma U251 cell apoptosis by impeding activity of (immuno)proteasome.

Authors:  Xianyun Qin; Jilan Liu; Dongfeng Pan; Wenyuan Ma; Panpan Cheng; Feng Jin
Journal:  Oncol Rep       Date:  2021-03-02       Impact factor: 3.906

Review 3.  Autophagic Organelles in DNA Damage Response.

Authors:  Jeongha Kim; Sungmin Lee; Hyunwoo Kim; Haksoo Lee; Ki Moon Seong; HyeSook Youn; BuHyun Youn
Journal:  Front Cell Dev Biol       Date:  2021-04-12

Review 4.  Corilagin in Cancer: A Critical Evaluation of Anticancer Activities and Molecular Mechanisms.

Authors:  Ashutosh Gupta; Amit Kumar Singh; Ramesh Kumar; Risha Ganguly; Harvesh Kumar Rana; Prabhash Kumar Pandey; Gautam Sethi; Anupam Bishayee; Abhay K Pandey
Journal:  Molecules       Date:  2019-09-19       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.